Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (161-170 of 211) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2007
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guidelineKatherine M W Pisters, William K Evans, Christopher G Azzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.
Investigational New Drugs|March 17, 2017
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II studyRavi Salgia, R Waide Weaver, Michael McCleod, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFICJhanelle E Gray, Augusto Villegas, Davey Daniel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2019
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)David R Spigel, Michael McCleod, Robert M Jotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJyoti D Patel, Mark A Socinski, Edward B Garon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Clinicopathologic Features of Advanced Squamous NSCLCMark A Socinski, Coleman Obasaju, David Gandara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
JCO Precision Oncology|April 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesMakenzi Evangelist, Bo Wang, James E Butrynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancerDavid R Spigel, Thomas J Ervin, Rodryg A Ramlau, et al.
Pageof 22

Showing results (161-170 of 211) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2007
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guidelineKatherine M W Pisters, William K Evans, Christopher G Azzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.
Investigational New Drugs|March 17, 2017
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II studyRavi Salgia, R Waide Weaver, Michael McCleod, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFICJhanelle E Gray, Augusto Villegas, Davey Daniel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2019
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)David R Spigel, Michael McCleod, Robert M Jotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJyoti D Patel, Mark A Socinski, Edward B Garon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Clinicopathologic Features of Advanced Squamous NSCLCMark A Socinski, Coleman Obasaju, David Gandara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
JCO Precision Oncology|April 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesMakenzi Evangelist, Bo Wang, James E Butrynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancerDavid R Spigel, Thomas J Ervin, Rodryg A Ramlau, et al.
Pageof 22